Vertex Appoints Charles Wagner as Chief Financial Officer
BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief…
Pharmaceuticals, Biotechnology and Life Sciences
BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the…
Patent issuance from Axcella’s broad Endogenous Metabolic Modulator (EMM) portfolio Claims cover methods of use of EMM compositions in liver…
PDUFA Target Action Date Set for November 10, 2019 BEDFORD, Mass.–(BUSINESS WIRE)—-Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused…
BergenBio said Tuesday that preclinical data strengthen bemcentinib’s potential in reversing tumour-mediated immunosuppression and therapy resistance, ina presentation by its academic collaborators at the American Association for Cancer Research (AACR) Annual Meeting 2019.
DUBLIN–(BUSINESS WIRE)–The “Global Track and Trace Solutions Market – Segmented by Product, Technology, Application, End-User, and Geography – Growth, Trends,…
SAN FRANCISCO–(BUSINESS WIRE)–JMP Group LLC (NYSE: JMP), an investment banking and alternative asset management firm, announced today that David Schechner…
Contract with GAF, a new private label line, and a pending storefront acquisition highlight vertical integration and growth as Innovest…
PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of…
– Avidity Effect of a Single – Chain Multispecific Centyrin Results in Potent Inhibition of Tumors Expressing MET and EGFR…